Navigation Links
Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the 'Ultimate Cardio Protection' Against Heart Attacks, Strokes and Heart Failure.
Date:12/10/2008

PALM, Pa., Dec. 10 /PRNewswire/ -- N3 Oceanic, Inc. announced the addition of Orosine to its heart-healthy Res-Q line of products. Orosine was developed by cardiologist Dr. Jeffrey Shapiro, MD, Assistant Professor of Internal Medicine / Cardiology at Columbia Presbyterian Hospital and NYU Langone Medical Center, who has been giving the formula to his patients for the last two years with life-changing results. Dr. Shapiro states, Orosine is the most significant natural product I have ever used for both the treatment and prevention of heart disease. This is the first product of its kind that works directly on the cells, to improve the delivery of oxygen to the heart, relax blood vessels and improve blood flow to the heart, thus reducing the risk of a heart attack."

Damage to the cells can occur from years of being overweight, stress, high blood pressure, high cholesterol, atherosclerosis, high blood sugar and existing heart disease. Most people have one or more of these risk factors as they begin to age. Many people may even be walking around feeling no symptoms at all. Orosine is essential for people with risk factors as well as those who have already suffered a heart attack, because it can help prevent secondary complications and ultimately heart failure.

Res-Q Orosine is a patented all-natural formula made up of two main ingredients, inosine and orotate, both naturally fermented from plant matter. These ingredients have years of research and clinical trials documenting their safety and powerful benefits to the weakened heart.

AboutN3Oceanic,Inc.

N3 Oceanic, Inc. has been a leader in the nutraceuticals industry since its inception over 20 years ago. N3's premium supplement line, Res-Q products, offer the finest proprietary blend of all-natural ingredients with a focus on heart health and prevention. For mo
'/>"/>

SOURCE N3 Oceanic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
3. Despite overeating, morbidly obese mice gain protection against diabetes
4. Alvarado Hospital Files Countersuit Against Blue Shield
5. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
6. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
7. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
8. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
9. $52.5 Million Settlement Against Sepracor Inc. Approved
10. The fight against colorectal cancer
11. Especially Yours and Paula Young Team up with Diahann Carroll and Jaclyn Smith in the Fight Against Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... Nov. 27 Team Garmin-Slipstream, t...ted to ethical sporting and developing the next ge...t it will become Team Garmin-Transitions with the ...f the team. Transitions Optical is the world,s lea...e most advanced photochromic technology in the wid...
(Date:11/27/2009)...ngs has announced that it has become a national sp...est nonprofit organizations dedicated to arthritis... Delray Beach, FL (Vocus) November ... a company specializing in the marketing and retai...s announced today that is has become a national sp...
(Date:11/27/2009)...ical, economic burdens, study predicts , ...of people with diabetes in the United States is ex...dy predicts. , That would bring the total by 20...up from 23.7 million today. , , At the same time...riple, the study also warns, rising from an estima...
(Date:11/27/2009)...trade; announced today that Spectrum Health (Grand...rprise orthopedic templating solution and its Trau... (PRWEB) November 27, 2009 -- Voyant Healt...nd Rapids, Michigan) has licensed its TraumaCad En...aumaCad Extend workflow solution, to allow its ort...
(Date:11/27/2009)...ufacturers who use medical load cells at the heart...by bringing in technology partner Flintec early in...ive medical manufacturers are calling in Flintec l...jects, ensuring that progress will not be constrai...tdated technology. , (PRW...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...rmed at the evolution of causal organisms of hit...ey warn is the result of overzealous use of antibi...cement by the U.S Centers For Disease Control (CDC...creating worry lines on many a health expert. ...
...y predictor for liver cancer, says a US study. ...ne biomarker,// researchers at Columbia University... a means for early detection of liver cancer, says...have been associated with the development of liver...
...weight successfully should drink at least two litr...ction Centre in the German state of Rhineland-Pala...ht people drank too little and often mistook thirs...r metabolism and also improve skin tone. The...
...growing incidents of suicides and fratricides in t...ay called for steps to "urgently" address the// is...ases continues to be a cause of concern and must b...es in 2006. There have been 21 cases this year alo...
...ntries, those called up to risk their lives in the... and even ill-treated. Apparently the US is no exc...red out their grievances during a hearing of the P...th care system as a labyrinth, said their families...
...maceuticals Incorporated, a global biotechnology c...a trial on new hepatitis C drug, telaprevir. The d..., it has been shown. The planned interim resu...f the Liver (EASL). This drug has an enormous...
Other Medicine News:Health News:Blood DNA Predicts Liver Cancer Early 2Health News:Antony Concerned Over Growing Suicide Rates in Armed Forces 2Health News:Military Healthcare Lacks Compassion, Say US Soldiers 2Health News:New Hepatitis C Drug Shows Promise 2
(Date:11/25/2009)..., , MOUNTAIN VIEW, Calif., Nov. 25 /PRNewsw... Phase II/III clinical data from the Company,s PRO...aluation in Crohn,s disease Trial) of Traficet-EN(... Crohn,s disease demonstrated clinical efficacy wi...he study demonstrated evidence of clinical efficac...
(Date:11/24/2009)..., , PITTSBURGH, Nov. 24 ... have been in coma for 23 years following an auto ...uring that time and was the subject of a Good Morn...red in the segment to illustrate how people with L...communication. ,, WHEN: Good Morning America -...
(Date:11/24/2009)..., , MADISON, N.J., Nov. 24 /PRNewswire-...: DGX ), the world,s leading provider of diagnos...hat it is scheduled to speak at the 21st Annual Pi.... The presentation is scheduled for Wednesday, De...ring the conference, the company will reaffirm its...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Bionovo Announces Pricing of Securities Offering 58766 1Bionovo Announces Pricing of Securities Offering 58766 2Bionovo Announces Pricing of Securities Offering 58766 3Yongye International Announces 2010 2012 Strategic Plan 14335 1Yongye International Announces 2010 2012 Strategic Plan 14335 2Yongye International Announces 2010 2012 Strategic Plan 14335 3Yongye International Announces 2010 2012 Strategic Plan 14335 4Yongye International Announces 2010 2012 Strategic Plan 14335 5Caraco Pharmaceutical Laboratories Ltd Closes Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram oxala 5189 1Caraco Pharmaceutical Laboratories Ltd Closes Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram oxala 5189 2
...T High-Risk Registry Data Shows Improved Symptomat...tients Treated with the MitraClip(R) System , , O...repair using the MitraClip(R) system in symptomati...al regurgitation (FMR) improves patient clinical s... 12-month data from the high-risk registry arm of ...
...RK, March 27 The Michael J. Fox Foundation announ... total to seven research teams working to improve ...nding was awarded under the Foundation,s Improvin...the Brain . The program is designed to address two...tive treatments for Parkinson,s disease: the need ...
Other Medicine Technology:MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up 2MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up 3Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinson's Disease 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: